

# ForPatients

by Roche

Neovascular Age-related Macular Degeneration Wet Age-Related Macular Degeneration  
Diabetic Macular Edema

## A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

**Trial Status**  
Not Yet Recruiting

**Trial Runs In**  
0 Countries

**Trial Identifier**  
NCT06680817 MR45586

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye, in real-world routine clinical practice over a 2-year patient follow-up period. Additionally, the FaReal study also aims to describe and evaluate health economic aspects of previous anti-VEGF treatments and current treatment with faricimab.

**Hoffmann-La Roche**  
Sponsor

**N/A**  
Phase

---

**NCT06680817 MR45586**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---